원문정보
피인용수 : 0건 (자료제공 : 네이버학술정보)
초록
영어
The pharmaceutical industry has an ongoing need for new, safe medicines with genuine biomedical effects. Most of the candidate molecules are far from becomes a drug, because of their pharmacokinetic and pharmacodynamic properties. The introduction of bioisostere to improve properties of molecules and to obtain new class of compound is currently increased. Silicon substitution of carbon of existing drugs is an attractive strategy to search a new candidate with improved biological and physicochemical properties. The fundamental differences between carbon and silicon can lead to improved profile of the silicon containing candidate, and could be exploited to get further benefit in drug design process.
목차
Abstract
1. Introduction
2. Stability of Silicon ContainingOrganic Molecu2. Stability of Silicon Containing Organic Moleculesles
3. Silicon Containing Ether in Drug Delivery
4. Silicon Isosteres in Inhibitors
5. Hydroxy and Dihydroxy and TrihydroxyAnalogue of Silic5. Hydroxy and Dihydroxy and Trihydroxy Analogue of Silicon
6. Limitations
7. Conclusion
Acknowledgments
References
1. Introduction
2. Stability of Silicon ContainingOrganic Molecu2. Stability of Silicon Containing Organic Moleculesles
3. Silicon Containing Ether in Drug Delivery
4. Silicon Isosteres in Inhibitors
5. Hydroxy and Dihydroxy and TrihydroxyAnalogue of Silic5. Hydroxy and Dihydroxy and Trihydroxy Analogue of Silicon
6. Limitations
7. Conclusion
Acknowledgments
References
저자정보
참고문헌
자료제공 : 네이버학술정보